Keen Vision Acquisition CORP 10-Q quarterly reports

Keen Vision Acquisition Corporation's Q2 2026 report details Nasdaq delisting, ongoing business combination search, and significant share redemptions, raising concerns about its future viability.

Keen Vision Acquisition Corporation reports Q1 2026 results while continuing to pursue a business combination with Medera Inc. and Novoheart Group Limited.

Keen Vision Acquisition Corporation reports a significant decline in Trust Account assets and a working capital deficit, raising substantial doubt about its ability to continue as a going concern without completing its proposed merger by November 27, 2025.

Keen Vision Acquisition Corporation reports a significant decline in cash and net income, facing going concern doubts as it extends its deadline to complete a merger with biopharmaceutical company Medera Inc.

Keen Vision Acquisition Corporation (KVAC) reports a net income of $568,171 for the quarter ended March 31, 2025, while continuing efforts to finalize a business combination, extending the deadline to May 27, 2025.

Keen Vision Acquisition Corporation reported a net income of $6.6 million for the nine months ended September 30, 2024, while progressing with its merger plans with Medera Inc.

Keen Vision Acquisition Corporation reported a net income of $5.04 million for the six months ended June 30, 2024, primarily driven by investment income from its trust account, while actively pursuing a business combination.

Keen Vision Acquisition Corporation reported a net income of $3.27 million for the quarter ended March 31, 2024, primarily driven by investment income from its trust account.